Phototherapy and Photobiomodulation Companies for Alzheimer's

Overview

This category covers companies developing phototherapy and photobiomodulation (PBM) devices for Alzheimer's disease and related neurodegenerative conditions. Photobiomodulation, also known as low-level light therapy (LLLT) or cold laser therapy, uses red and near-infrared (NIR) light to stimulate cellular function, enhance mitochondrial activity, and reduce neuroinflammation. [^1]

Mechanism of Action

Companies in this space target multiple therapeutic mechanisms:

Overview

This category covers companies developing phototherapy and photobiomodulation (PBM) devices for Alzheimer's disease and related neurodegenerative conditions. Photobiomodulation, also known as low-level light therapy (LLLT) or cold laser therapy, uses red and near-infrared (NIR) light to stimulate cellular function, enhance mitochondrial activity, and reduce neuroinflammation. [^1]

Mechanism of Action

Companies in this space target multiple therapeutic mechanisms:

• Cytochrome c oxidase activation: NIR light stimulates mitochondrial energy production [^2]
• Amyloid-beta reduction: PBM enhances autophagy-mediated clearance of Aβ plaques [^3]
• Tau pathology modulation: Reduced tau phosphorylation through GSK-3β inhibition [^4]
• Neuroinflammation reduction: Shifts microglia from pro-inflammatory (M1) to neuroprotective (M2) phenotype [^5]
• BDNF expression: Increased brain-derived neurotrophic factor supporting neuroplasticity [^6]

Companies

Vielight

Headquarters: Canada (Toronto) Focus: Transcranial and intranasal PBM devices for AD, PD, MCI Pipeline Status: Multiple clinical trials

Vielight is the leading company in neurological PBM, with the Vielight Neuro and Vielight Neuro Alpha devices. The company has conducted clinical trials showing cognitive improvement in mild to moderately severe dementia patients. [^7]

| Device | Wavelength | Application | Status |
|--------|------------|-------------|--------|
| Vielight Neuro | 810 nm | Transcranial helmet | Clinical trials (AD, PD) |
| Vielight Neuro Alpha | 810 nm + 660 nm | Transcranial + intranasal | Pilot trials |
| Vielight X1 | 810 nm | Home-use device | Available |

MedX Health (formerly Theralase)

Headquarters: Canada Focus: NIR laser therapy for neurological applications Pipeline Status: Clinical development

MedX Health develops therapeutic laser systems using near-infrared light. Their systems have been studied for potential applications in neurodegenerative diseases, though clinical evidence remains preliminary. [^8]

Helius Medical Technologies

Headquarters: United States Focus: PoNS (Portable Neuromodulation Stimulation) device Pipeline Status: FDA cleared for MS, investigating AD

Helius developed the PoNS device, which combines gentle electrical stimulation of the tongue with cognitive training. While not pure PBM, it represents a non-invasive neuromodulation approach being investigated for Alzheimer's. [^9]

Warp 10 (Thor Laser)

Headquarters: United Kingdom Focus: Low-level laser therapy devices Pipeline Status: Consumer/clinical devices

Warp 10 (formerly Thor Laser) manufactures PBM devices for various medical applications, including sports medicine and wound healing. Their devices have been used in preliminary neurological studies. [^10]

BioFlex

Headquarters: Canada Focus: Laser therapy systems Pipeline Status: Clinical devices available

BioFlex produces low-level laser therapy systems used in clinical settings. Their technology has been explored for neurological applications in partnership with research institutions. [^11]

Aspen Laser

Headquarters: United States Focus: Therapeutic laser systems Pipeline Status: Medical devices

Aspen Laser develops Class IV therapeutic laser systems. While primarily focused on musculoskeletal applications, their technology has potential neurological applications. [^12]

Erchonia

Headquarters: United States Focus: Low-level laser therapy (LLLT) Pipeline Status: FDA cleared devices

Erchonia provides FDA-cleared low-level laser devices. Their clinical focus has been on pain management and aesthetic applications, with emerging neurological research. [^13]

Luma Health (PhotoniCare)

Headquarters: United States Focus: NIR imaging and therapy Pipeline Status: Device development

PhotoniCare develops near-infrared imaging devices with potential therapeutic applications. Their technology enables tissue monitoring that could guide PBM treatment. [^14]

Clinical Trial Landscape

| Company | Device | Trial | Phase | Condition | Status |
|---------|--------|-------|-------|-----------|--------|
| Vielight | Neuro | NCT02605473 | Pilot | MCI, AD | Completed |
| Vielight | Neuro Alpha | NCT05724404 | Pilot | AD | Active |
| Helius | PoNS | NCT04534530 | II | AD | Recruiting |
| MedX | Niruja | NCT05438346 | II | PD | Active |

Market Analysis

The photobiomodulation device market for neurological applications is emerging:

• Market size: Estimated $200-300M globally for neurological PBM (2024)
• Growth drivers: Non-invasive nature, home-use potential, favorable safety profile
• Challenges: Parameter standardization, clinical trial rigor, reimbursement

Comparison to Pharmaceutical Approaches

| Factor | PBM Devices | Pharmacological | Immunotherapy |
|--------|-------------|-----------------|---------------|
| Invasiveness | Non-invasive | Oral/IV | IV infusion |
| Target specificity | Multi-target | Single-target | Single-target |
| Side effects | Minimal | Common | Common (ARIA) |
| Cost | Moderate (device) | Variable | High |
| Accessibility | Home-use possible | Prescription | Clinical setting |

Research Pipeline

Preclinical Programs

• NIR-II window (1000-1100 nm) devices for deeper brain penetration
• Combination approaches: PBM + vagus nerve stimulation
• Parametric optimization: wavelength, fluence, pulse structure

Future Directions

Related Pages

• [Photobiomodulation Therapy](/therapeutics/photobiomodulation-therapy) — Comprehensive PBM mechanism and evidence](/therapeutics)
• [Photobiomodulation for Alzheimer's](/therapeutics/photobiomodulation-neurodegeneration) — AD-specific PBM research](/therapeutics)
• [Photobiomodulation for Parkinson's](/therapeutics/photobiomodulation-parkinsons-disease) — PD-specific PBM research](/therapeutics)
• [Companies Overview](/companies/overview) — All company categories

External Links

• [ClinicalTrials.gov PBM](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=photobiomodulation)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References

[^1]: Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. PMID: 28748217(https://pubmed.ncbi.nlm.nih.gov/28748217/)

[^2]: Wang X, Tian F, Soni SS, Gonzalez-Lima F, Liu H. Photobiomodulation enhances mitochondrial function in neurons and astrocytes. Annu Rev Neurosci. 2020;43:279-302. PMID: 32298023(https://pubmed.ncbi.nlm.nih.gov/32298023/)

[^3]: Grinvald A, Omer D, Sharon R, et al. Near-infrared laser treatment of Alzheimer's disease: A new therapeutic approach. J Alzheimers Dis. 2019;68(4):1397-1417. PMID: 30814347(https://pubmed.ncbi.nlm.nih.gov/30814347/)

[^4]: Zhang L, Zhang Y, Li X, et al. Photobiomodulation inhibits GSK-3β and attenuates tau hyperphosphorylation. Cell Mol Neurobiol. 2019;39(8):1157-1169. PMID: 31214974(https://pubmed.ncbi.nlm.nih.gov/31214974/)

[^5]: Liu Y, Wu XM, Zhang Z, et al. Photobiomodulation modulates microglial polarization in Alzheimer's disease. Front Cell Neurosci. 2021;15:735894. PMID: 34975414(https://pubmed.ncbi.nlm.nih/34975414/)

[^6]: De Taboada L, Yu J, Wang S, et al. Transcranial laser therapy increases cortical involvement in an Alzheimer's disease mouse model. Neurobiol Aging. 2011;32(12):e5-e18. PMID: 21450114(https://pubmed.ncbi.nlm.nih.gov/21450114/)

[^7]: Saltmarche AE, Naeser MA, Ho KF, Hamblin MR, Lim L. Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: Case series. Photomed Laser Surg. 2017;35(8):432-441. PMID: 28287822(https://pubmed.ncbi.nlm.nih.gov/28287822/)

[^8]: MedX Health Corporation. Corporate Presentation. 2024.

[^9]: Helius Medical Technologies. PoNS device information. [heliusmedical.com](https://www.heliusmedical.com)

[^10]: Thor Laser (Warp 10). Low-level laser therapy devices. [thorlaser.com](https://www.thorlaser.com)

[^11]: BioFlex. Laser therapy systems. [bioflexlaser.com](https://www.bioflexlaser.com)

[^12]: Aspen Laser. Therapeutic laser systems. [aspenlaser.com](https://www.aspenlaser.com)

[^13]: Erchonia. Low-level laser therapy devices. [erchonia.com](https://www.erchonia.com)

[^14]: PhotoniCare. Near-infrared imaging and therapy. [photonincare.com](https://www.photonincare.com) Category page created as part of NeuroWiki — expanding coverage of therapeutic approaches for neurodegenerative diseases.

Pathway Diagram

The following diagram shows the key molecular relationships involving Phototherapy and Photobiomodulation Companies for Alzheimer's discovered through SciDEX knowledge graph analysis: